Program
Dabigatran
Also written as “Dabigatran etexilate”, “dabigatran etexilate” and “Dabigatran Etexilate”.
Its studies are mostly in Venous Thromboembolism · Atrial Fibrillation · Thromboembolism · Thrombosis · Renal Insufficiency, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 740 open or running | phase 4since Aug 16, 2010 | Sep 8, 2005 | none ahead |
| Merck | 20 open or running | phase 1since Jun 3, 2011 | Jun 3, 2011 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 1since Apr 3, 2018 | Apr 3, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 15 studies since Oct 20, 2010.
- Jun 20, 201431 phase 1 studiesBoehringer Ingelheim · NCT02173717, NCT02171624, NCT02171611 and 28 more
- Jun 20, 20142 phase 2 studies in Venous ThromboembolismBoehringer Ingelheim · NCT02170935, NCT02170701
- Jul 2, 2014Phase 1 study in Renal InsufficiencyBoehringer Ingelheim · NCT02182024 · 35 enrolled
- Jul 21, 2014Phase 3 study in Venous ThromboembolismBoehringer Ingelheim · NCT02197416 · 214 enrolled · United States, Austria, Belgium and more
- Aug 21, 2014Phase 2 study in Venous ThromboembolismBoehringer Ingelheim · NCT02223260 · 8 enrolled · Canada, France, Russian Federation
- Sep 10, 2014Phase 3 study in StrokeBoehringer Ingelheim · NCT02239120 · 5,390 enrolled · United States, Argentina, Australia and more
- Jan 27, 2015Phase 4 study in Atrial FibrillationBoehringer Ingelheim · NCT02348723 · 678 enrolled · United States, Belgium, Canada and more
- Sep 21, 2016Phase 3 study in ThromboembolismBoehringer Ingelheim · NCT02913326 · 120 enrolled · France, Germany, India and more
- Feb 28, 2017Phase 1 study in HealthyBoehringer Ingelheim · NCT03070171 · 160 enrolled · Japan
- Mar 16, 2017Phase 1 study in Healthy VolunteersBoehringer Ingelheim · NCT03086356 · 12 enrolled · China
- May 4, 2017Phase 1 study in Non-alcoholic Fatty Liver DiseaseBoehringer Ingelheim · NCT03143166 · 36 enrolled · Japan
- Oct 12, 2017Phase 1 study in Renal InsufficiencyMerck · NCT03311841 · 32 enrolled · United States
- Apr 3, 2018Merck KGaA, Darmstadt, Germany's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT03492437 · 20 enrolled · Germany
- Feb 4, 2020Phase 1 study in HealthyBoehringer Ingelheim · NCT04257032 · 28 enrolled · Germany
TargetBeta
“Thrombin inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 77 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04257032Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 23, 2020 | 28 |
| NCT03492437Carcinoma, Non-Small-Cell Lung · Germany | 1 | Completed | Merck KGaA, Darmstadt, Germany | Aug 27, 2018 | 20 |
| NCT03311841Renal Insufficiency · United States | 1 | Completed | Merck | Aug 2, 2018 | 32 |
| NCT03143166Non-alcoholic Fatty Liver Disease · Japan | 1 | Completed | Boehringer Ingelheim | Jul 27, 2017 | 36 |
| NCT03086356Healthy Volunteers · China | 1 | Completed | Boehringer Ingelheim | Sep 12, 2017 | 12 |
| NCT03070171Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Jun 16, 2017 | 160 |
| NCT02913326Thromboembolism · France, Germany, India and more | 3 | Completed | Boehringer Ingelheim | Jun 22, 2018 | 120 |
| NCT02348723Atrial Fibrillation · United States, Belgium, Canada and more | 4 | Completed | Boehringer Ingelheim | Nov 11, 2016 | 678 |
| NCT02239120Stroke · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Aug 14, 2018 | 5,390 |
| NCT02223260Venous Thromboembolism · Canada, France, Russian Federation | 2 | Completed | Boehringer Ingelheim | Jan 2016 | 8 |
| NCT02197416Venous Thromboembolism · United States, Austria, Belgium and more | 3 | Completed | Boehringer Ingelheim | Oct 16, 2019 | 214 |
| NCT02182024Renal Insufficiency | 1 | Completed | Boehringer Ingelheim | Mar 2006 | 35 |
| NCT02173717Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2009 | 24 |
| NCT02171624Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2009 | 42 |
| NCT02171611Healthy | 1 | Completed | Boehringer Ingelheim | May 2009 | 30 |
| NCT02171598Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2009 | 44 |
| NCT02171585Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2008 | 20 |
| NCT02171546Healthy | 1 | Terminated | Boehringer Ingelheim | Jan 2008 | 42 |
| NCT02171533Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2008 | 40 |
| NCT02171507Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2006 | 24 |
| NCT02171468Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2006 | 48 |
| NCT02171455Healthy | 1 | Completed | Boehringer Ingelheim | Jan 2006 | 10 |
| NCT02171052Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2006 | 24 |
| NCT02171039Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2006 | 24 |
| NCT02171026Healthy | 1 | Completed | Boehringer Ingelheim | Jun 2006 | 24 |
| NCT02171000Healthy | 1 | Completed | Boehringer Ingelheim | May 2005 | 7 |
| NCT02170974Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2004 | 28 |
| NCT02170935Venous Thromboembolism | 2 | Completed | Boehringer Ingelheim | Jun 2002 | 62 |
| NCT02170922Healthy | 1 | Completed | Boehringer Ingelheim | Aug 1999 | 6 |
| NCT02170909Healthy | 1 | Completed | Boehringer Ingelheim | Jun 2005 | 42 |
| NCT02170896Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2001 | 16 |
| NCT02170844Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2004 | 40 |
| NCT02170831Healthy | 1 | Completed | Boehringer Ingelheim | Jul 1999 | 40 |
| NCT02170792Healthy | 1 | Completed | Boehringer Ingelheim | Mar 2001 | 30 |
| NCT02170766Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2000 | 48 |
| NCT02170740Healthy | 1 | Completed | Boehringer Ingelheim | Jan 2000 | 26 |
| NCT02170701Venous Thromboembolism | 2 | Completed | Boehringer Ingelheim | Jun 2001 | 289 |
| NCT02170675Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2009 | 24 |
| NCT02170636Healthy | 1 | Completed | Boehringer Ingelheim | Mar 2002 | 15 |
| NCT02170623Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2002 | 12 |
| NCT02170610Healthy | 1 | Completed | Boehringer Ingelheim | May 2002 | 18 |
| NCT02170597Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2003 | 12 |
| NCT02170584Healthy | 1 | Completed | Boehringer Ingelheim | Mar 2001 | 30 |
| NCT02170571Hepatic Insufficiency | 1 | Completed | Boehringer Ingelheim | Dec 2005 | 24 |
| NCT02170116Healthy | 1 | Completed | Boehringer Ingelheim | Dec 1998 | 40 |
| NCT02164864Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Jun 5, 2017 | 2,725 |
| NCT02044367Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Apr 2014 | 54 |
| NCT01896297Atrial Fibrillation · United States | 4 | Completed | Boehringer Ingelheim | Oct 2015 | 63 |
| NCT01895777Venous Thromboembolism · United States, Argentina, Austria and more | 3 | Completed | Boehringer Ingelheim | Oct 16, 2019 | 267 |
| NCT01773174Venous Thromboembolism · United States | 2 | Withdrawn | Boehringer Ingelheim | Dec 2015 | 0 |
| NCT01711853Renal Insufficiency, Chronic · Netherlands | 1 | Completed | Boehringer Ingelheim | Dec 2013 | 19 |
| NCT01505881Thromboembolism · Belgium, Canada, Czech Republic and more | 2 | Terminated | Boehringer Ingelheim | Jun 2013 | 158 |
| NCT01493557Atrial Fibrillation · United States, Canada | 4 | Completed | Boehringer Ingelheim | Jul 2014 | 1,067 |
| NCT01452347Heart Valve Diseases · Belgium, Canada, Czech Republic and more | 2 | Terminated | Boehringer Ingelheim | Jun 2013 | 328 |
| NCT01379300Thrombosis | 1 | Completed | Merck | Dec 2011 | 42 |
| NCT01306162Healthy · Germany | 1 | Completed | Boehringer Ingelheim | May 2011 | 36 |
| NCT01290757Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Apr 2011 | 180 |
| NCT01241539Cardiovascular Diseases · Germany | 1 | Completed | Boehringer Ingelheim | May 2011 | 7 |
| NCT01227629Atrial Fibrillation · United States, Denmark, Sweden | 2 | Completed | Boehringer Ingelheim | Nov 2004 | 502 |
| NCT01225822Venous Thromboembolism · Austria, Belgium, Czech Republic and more | 2 | Completed | Boehringer Ingelheim | Aug 2003 | 1,973 |
How it is read
Names in the registry
- “Dabigatran etexilate”, 27 entries
- “dabigatran etexilate”, 21 entries
- “Dabigatran”, 7 entries
- “Dabigatran Etexilate”, 6 entries
- “dabigatran with ASA”, 6 entries
Conditions, from the studies’ own filings
- Venous Thromboembolism, 12 studies
- Atrial Fibrillation, 9 studies
- Thromboembolism, 7 studies
- Thrombosis, 2 studies
- Renal Insufficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.